Our Opinion

Nuvation Bio Inc. is on the Cruelty Free Investing list for exploiting animals because the company does animal testing to assess a product’s safety profile.

Supporting Evidence:

The company stated in the following report that they exploit animals for product testing.

“If you look at some of our preclinical xenograft data with NUV-422, in this particular experiment we have shown that NUV-422 is superior to standard of care Temozolomide in an in vivo xenograft model of GBM. So if you look at this study here, over approximately a month period of time, untreated animals had their tumors grow significantly in the black solid line, animals treated with standard of care Temozolomide in the purple line still had significant growth of their tumors.” (Page 3) Read the full document

Company Description

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company’s lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation; NUV-569, a differentiated oral small molecule selective inhibitor of the Wee1 kinase for DNA damage repair; NUV-1182, an adenosine receptor inhibitor; and drug-drug conjugate (DDC) platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to anti-cancer warheads of existing drugs, as well as PARP inhibitor to address ER+ breast and ovarian cancer. The company was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. Nuvation Bio Inc. was founded in 2018 and is headquartered in New York, New York.

Company Website: https://www.nuvationbio.com